Arnie Oronsky, Ph.D. is a founder and board member of Centrexion Therapeutics. Arnie currently serves as a general partner and managing director at InterWest Partners LLC, a venture capital firm. Earlier in his career, Arnie led pharmaceutical research as vice president for discovery research for the Lederle Laboratories division of American Cyanamid Company. He is a board member of Applied Genetic Technologies Corporation, Drais Pharmaceuticals, Dynavax Technologies, EpicentRx, Integrated Diagnostics, PMV Pharma, Potenza Therapeutics, Sera Prognostics, TESARO and Tizona Therapeutics. Arnie holds a B.A. degree from New York University, a Ph.D. in Immunology from Columbia University and is a senior lecturer at Johns Hopkins Medical School.
Douglas Fisher, MD has served as our President since June 2021. He is currently a Venture Partner at Revelation Partners, which he joined in 2020, and an Executive-in Residence at InterWest Partners. Dr. Fisher joined InterWest’s healthcare team in 2009, focusing on biopharmaceutical, diagnostic and medical device investments. He is a board member of Gynesonics, Indi Molecular, Precipio Diagnostics (NASDAQ: PRPO), and WeavR Health. He is also actively involved in InterWest’s investments in PMV Pharma, Potenza Therapeutics, Sera Prognostics (NASDAQ: SERA, where he serves as the Chief Business Officer), and Tizona Therapeutics. Prior to joining InterWest, Dr. Fisher was a vice president at New Leaf Venture Partners where he spent three years focusing on biopharmaceutical, medical device, and diagnostics investments including Pearl Therapeutics, Interlace Medical (Acquired by Hologic), and Stromedix (Acquired by Biogen Idec). Prior to joining New Leaf, Dr. Fisher was a project leader with The Boston Consulting Group where he was a member of the Health Care Practice Area, consulting for leading pharmaceutical and biotech companies. Previously, Dr. Fisher worked for Centocor (a J&J operating company) in the Global Biologic Strategic Marketing Group. He received an A.B. in Economics and a B.S. in Biology, from Stanford. Dr. Fisher has a M.D. from the University of Pennsylvania School of Medicine and a M.B.A. from The Wharton School, University of Pennsylvania.
Robert Flaherty is a prominent health care executive with a distinguished 35-year track record in the clinical laboratory environment and in vitro diagnostics.
He currently is Operating Partner, Health Care Services for Behrman Capital. Prior to joining Behrman Capital, Flaherty was President and CEO of Athena Diagnostics, which he built into one of the largest specialty commercial reference laboratories. He subsequently led the company to sequential acquisition by Elan, a publicly traded, NYSE company, followed by Behrman Capital and later by Fisher Scientific.
Earlier, Flaherty served as President of Becton Dickinson Medical and President of Becton Dickinson Vacutainer Systems from 1982 through 1992, a period of multifold expansion and dominance in the marketplace.
He currently serves on the Board of Directors of Behrman Capital's portfolio company Ark Holdings, a multi-state nursing home operator. He is also on the Board of the Chernobyl Children's Project (USA), a charitable organization assisting children afflicted by the Chernobyl nuclear explosion.
Flaherty holds a BS in industrial engineering from Lehigh University, and an MBA from Harvard Business School.
AkaRx, Applied Genetic Technologies, Arcion Therapeutics, BioTransplant, Drais Pharmaceuticals, Dynavax Technologies Corporation, Integrated Diagnostics, Kanisa Pharmaceuticals, MacroGenics, Metabasis Therapeutics, Paracor Medical, RadioRx, and Tesaro
Cardiac Dimensions, Gynesonics, Obalon Therapeutics, and Sera Prognostics